{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:22:12Z","timestamp":1782926532117,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunogenetics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00251-022-01291-4","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T01:02:17Z","timestamp":1672016537000},"page":"145-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of regulatory T cells (Tregs) and Foxp3 methylation level in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9763-1586","authenticated-orcid":false,"given":"Shahla\u2019a Fadhil","family":"Sabir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam Francis","family":"Matti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wifaq Mahmood Ali","family":"Alwatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"issue":"3","key":"1291_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12185-014-1627-6","volume":"100","author":"MD Ali","year":"2014","unstructured":"Ali MD, Badi AI, Al-Zebari SSM, Al-Allawi NAS (2014) Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country. Int J Hematol 100(3):274\u2013280. https:\/\/doi.org\/10.1007\/s12185-014-1627-6","journal-title":"Int J Hematol"},{"issue":"6","key":"1291_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122(6):872\u2013884. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"19","key":"1291_CR3","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR (2013) Early molecular response and female sex strongly predict stable undetectable BCR- ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121(19):3818\u20133824","journal-title":"Blood"},{"issue":"21","key":"1291_CR4","first-page":"9188","volume":"28","author":"Y Cheng","year":"2017","unstructured":"Cheng Y, Yang G, Sun M, Chang K, Long R et al (2017) The expression and clinical significance of Treg cells in chronic myelocytic leukemia. Biomed Res 28(21):9188\u20139192","journal-title":"Biomed Res"},{"issue":"5","key":"1291_CR5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.juro.2007.01.010","volume":"177","author":"S Cottrell","year":"2007","unstructured":"Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A et al (2007) Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 177(5):1753\u20131758. https:\/\/doi.org\/10.1016\/j.juro.2007.01.010","journal-title":"J Urol"},{"issue":"4","key":"1291_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol 4(4):330\u2013336. https:\/\/doi.org\/10.1038\/ni904. (Epub 2003 Mar 3)","journal-title":"Nat Immunol"},{"issue":"23","key":"1291_CR7","doi-asserted-by":"publisher","first-page":"e151797","DOI":"10.1172\/jci.insight.151797","volume":"6","author":"M Hinterbrandner","year":"2021","unstructured":"Hinterbrandner M, Rubino V, Stoll C, Forster S, Schn\u00fcriger N et al (2021) Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. JCI Insight 6(23):e151797.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.151797","journal-title":"JCI Insight"},{"key":"1291_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF et al (2020) European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"10","key":"1291_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376(10):917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"issue":"5609","key":"1291_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057\u20131061. https:\/\/doi.org\/10.1126\/science.1079490","journal-title":"Science"},{"key":"1291_CR11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","volume":"35","author":"YC Hsieh","year":"2021","unstructured":"Hsieh YC, Kirschner K, Copland M (2021) Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia 35:1229\u20131242. https:\/\/doi.org\/10.1038\/s41375-021-01238-w","journal-title":"Leukemia"},{"issue":"9","key":"1291_CR12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL et al (2017) CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 129(9):1166\u20131176. https:\/\/doi.org\/10.1182\/blood-2016-10-745992","journal-title":"Blood"},{"issue":"469","key":"1291_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM (2017) Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol 8(469):1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2017.00469","journal-title":"Front Immunol"},{"issue":"61","key":"1291_CR14","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.18632\/oncotarget.22279","volume":"8","author":"M Ilander","year":"2017","unstructured":"Ilander M, Mustjoki S (2017) Immune control in chronic myeloid leukemia. Oncotarget 8(61):102763\u2013102764","journal-title":"Oncotarget"},{"issue":"2","key":"1291_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H (2016) Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 91(2):252\u2013265. https:\/\/doi.org\/10.1002\/ajh.24275","journal-title":"Am J Hematol"},{"issue":"3","key":"1291_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","volume":"13","author":"JA Kennedy","year":"2018","unstructured":"Kennedy JA, Hobbs G (2018) Tyrosine kinase inhibitors in the treatment of chronic phase CML: strategies for frontline decision-making. Curr Hematol Malig Rep 13(3):202\u2013211. https:\/\/doi.org\/10.1007\/s11899-018-0449-7","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"1291_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000552","volume":"8","author":"N Klumper","year":"2020","unstructured":"Klumper N, Ralser DJ, Bawden EG, Landsberg J, Zarbl R et al (2020) LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer 8(1):e000552. https:\/\/doi.org\/10.1136\/jitc-2020-000552","journal-title":"J Immunother Cancer"},{"key":"1291_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002591","volume":"9","author":"S Koyama","year":"2021","unstructured":"Koyama S, Nishikawa H (2021) Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer 9:e002591. https:\/\/doi.org\/10.1136\/jitc-2021-002591","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1291_CR19","first-page":"34","volume":"11","author":"HA Labib","year":"2015","unstructured":"Labib HA, Haggag R (2015) CD4 + CD25 + high FoxP3 regulatory T-Cells in typical and atypical Philadelphia+ve CML as regards response to imatinib therapy. J Am Sci 11(5):34\u201341","journal-title":"J Am Sci"},{"issue":"10","key":"1291_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013267","volume":"5","author":"J Liu","year":"2010","unstructured":"Liu J, Lluis A, Illi S, Layland L, Olek S et al (2010) T regulatory cells in cord blood\u2013FOXP3 demethylation as reliable quantitative marker. PLoS One 5(10):e13267. https:\/\/doi.org\/10.1371\/journal.pone.0013267","journal-title":"PLoS ONE"},{"key":"1291_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4274\/Tjh.2Oi2.oi35","volume":"30","author":"BF Matti","year":"2013","unstructured":"Matti BF, Naji AS, Alwan AF (2013) Evaluation of the safety of imatin\u00eeb mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronie phase:single-center study. Turk J Hematol 30:387\u2013393. https:\/\/doi.org\/10.4274\/Tjh.2Oi2.oi35","journal-title":"Turk J Hematol"},{"key":"1291_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4172\/2167-0501.1000263","volume":"8","author":"M Nachi","year":"2019","unstructured":"Nachi M, Kihel I, Guella D, Dali-Ali A, Abed A et al (2019) Sex and major molecular response to imatinib treatment for patients with chronic myeloid leukemia. Biochem Pharmacol 8:263. https:\/\/doi.org\/10.4172\/2167-0501.1000263","journal-title":"Biochem Pharmacol"},{"key":"1291_CR23","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.exphem.2010.09.004","volume":"38","author":"JM Rojas","year":"2010","unstructured":"Rojas JM, Wang L, Owen S, Knight K, Watmough SJ et al (2010) Naturally occurring CD4 + CD25 + FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Exp Hematol 38:1209\u20131218. https:\/\/doi.org\/10.1016\/j.exphem.2010.09.004","journal-title":"Exp Hematol"},{"issue":"6","key":"1291_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D et al (2016) Two FOXP3 + CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22(6):679\u2013684. https:\/\/doi.org\/10.1038\/nm.4086","journal-title":"Nat Med"},{"key":"1291_CR25","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saubele","year":"2016","unstructured":"Saubele S, Richter J, Hochhaus A, Mahon FX (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:1638\u20131647. https:\/\/doi.org\/10.1038\/leu.2016.115","journal-title":"Leukemia"},{"issue":"2","key":"1291_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4161\/epi.6.2.13755","volume":"6","author":"J Sehouli","year":"2011","unstructured":"Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmuller U et al (2011) Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 6(2):236\u2013246. https:\/\/doi.org\/10.4161\/epi.6.2.13755","journal-title":"Epigenetics"},{"issue":"15179","key":"1291_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang SJ, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5(15179):1\u20139. https:\/\/doi.org\/10.1038\/srep15179","journal-title":"Sci Rep"},{"key":"1291_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/01621459.1974.10480196","volume":"69","author":"MA Stephens","year":"1974","unstructured":"Stephens MA (1974) EDF statistics for Good ness of fit and some comparisons. J Am Stat Assoc 69:730\u2013737","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"1291_CR29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191009","volume":"217","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Nishikawa H, Noguchi S et al (2020) Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med 217(2):e20191009. https:\/\/doi.org\/10.1084\/jem.20191009","journal-title":"J Exp Med"},{"issue":"2","key":"1291_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","volume":"129","author":"A Tarafdar","year":"2017","unstructured":"Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J et al (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood 129(2):199\u2013208. https:\/\/doi.org\/10.1182\/blood-2016-09-742049","journal-title":"Blood"},{"issue":"2","key":"1291_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/0008-5472.CAN-08-2361","volume":"69","author":"G Wieczorek","year":"2009","unstructured":"Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S et al (2009) Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 69(2):599\u2013608. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2361","journal-title":"Cancer Res"},{"issue":"10","key":"1291_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1084\/jem.20120822","volume":"209","author":"M Yadav","year":"2012","unstructured":"Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M et al (2012) Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 209(10):1713\u20131722. https:\/\/doi.org\/10.1084\/jem.20120822","journal-title":"J Exp Med"},{"issue":"6","key":"1291_CR33","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1080\/08820139.2018.1480029","volume":"47","author":"P Zafari","year":"2018","unstructured":"Zafari P, Yari K, Mostafaei S, Iranshahi N, Assar S et al (2018) Analysis of Helios gene expression and Foxp3 TSDR methylation in the newly diagnosed rheumatoid arthritis patients. Immunol Invest 47(6):632\u2013642. https:\/\/doi.org\/10.1080\/08820139.2018.1480029","journal-title":"Immunol Invest"},{"issue":"4","key":"1291_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10147-013-0615-9","volume":"19","author":"AM Zahran","year":"2014","unstructured":"Zahran AM, Badrawy H, Ibrahim A (2014) Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients. Int J Clin Oncol 19(4):753\u2013760. https:\/\/doi.org\/10.1007\/s10147-013-0615-9","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1291_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1076029612454937","volume":"20","author":"AM Zahran","year":"2012","unstructured":"Zahran AM, Elsayh KI (2012) CD4+ CD25 + High Foxp3+ regulatory T cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut Children Hospital. Clin Appl Thromb Hemost 20(1):61\u201367. https:\/\/doi.org\/10.1177\/1076029612454937","journal-title":"Clin Appl Thromb Hemost"},{"issue":"153","key":"1291_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-13-153","volume":"13","author":"C Zhuo","year":"2014","unstructured":"Zhuo C, Li Z, Xu Y, Wang Y, Li Q et al (2014) Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival. Mol Cancer 13(153):1\u201313. https:\/\/doi.org\/10.1186\/1476-4598-13-153","journal-title":"Mol Cancer"}],"container-title":["Immunogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00251-022-01291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00251-022-01291-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00251-022-01291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T06:03:12Z","timestamp":1679724192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00251-022-01291-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s00251-022-01291-4","relation":{},"ISSN":["0093-7711","1432-1211"],"issn-type":[{"value":"0093-7711","type":"print"},{"value":"1432-1211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"5 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval is sought from the scientific ethical committee of the college of medicine \/Baghdad University (Date 27\/2\/2019 \/No.365) and this study was performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent is obtained from each participant prior to enrollment in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}